



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Mercè Cases,
✉ merce.cases@patientadvocacy.eu
Rachel Giles,
✉ rachelhelengiles@gmail.com

[†]These authors have contributed equally to this work and share last authorship

RECEIVED 10 November 2025

ACCEPTED 11 November 2025

PUBLISHED 21 November 2025

CITATION

Cases M, Giles R, Ágh T, Piggin M, Geissler J, Racovita M, Hagymásy J, Ruth Wogu L, Józwiak Á, Hyseni-Bocolli A, Hosszú D, Plate A and EuroACT Working Group (2025) Correction: Methodological study protocol for the European Atlas of clinical trials in cancer and haematology. *Front. Pharmacol.* 16:1743351. doi: 10.3389/fphar.2025.1743351

COPYRIGHT

© 2025 Cases, Giles, Ágh, Piggin, Geissler, Racovita, Hagymásy, Ruth Wogu, Józwiak, Hyseni-Bocolli, Hosszú, Plate and EuroACT Working Group. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Methodological study protocol for the European Atlas of clinical trials in cancer and haematology

Mercè Cases^{1*}, Rachel Giles^{2*}, Tamás Ágh³, Maria Piggin⁴, Jan Geissler^{1,5}, Monica Racovita⁶, Judit Hagymásy³, Lora Ruth Wogu⁷, Ákos Józwiak³, Albina Hyseni-Bocolli⁸, Dalma Hosszú^{3,9†}, Ananda Plate^{1,2†} and EuroACT Working Group

¹European Patient Advocacy Institute, Riemerling, Germany, ²VHL Europa, Vlaardingen, Netherlands, ³Syreon Research Institute, Budapest, Hungary, ⁴PNH Global Alliance, Tiel, Netherlands, ⁵Workgroup of European Cancer Patient Advocacy Networks, Barcelona, Spain, ⁶Myeloma Patients Europe, Brussels, Belgium, ⁷European Sickle Cell Federation-ESCF, Dublin, Ireland, ⁸Childhood Cancer International – Europe, Vienna, Austria, ⁹University of Pécs Institute of Psychology, Pécs, Hungary

KEYWORDS

cancer, haematology, rare disease, patient, patient reported outcome, clinical trials

A Correction on

Methodological study protocol for the European Atlas of clinical trials in cancer and haematology

by Cases M, Giles R, Ágh T, Piggin M, Geissler J, Racovita M, Hagymásy J, Ruth Wogu L, Józwiak Á, Hyseni-Bocolli A, Hosszú D, Plate A and EuroACT Working Group (2025). *Front. Pharmacol.* 16: 1558556. doi: 10.3389/fphar.2025.1558556

Authors **Judit Hagymásy**, **Ákos Józwiak** and **Dalma Hosszú** were erroneously assigned to affiliation 4 PNH Global Alliance, Tiel, Netherlands. This affiliation has now been removed for author Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.

Affiliation 3 Syreon Research Institute, Budapest, Hungary was omitted for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú. This affiliation has now been added for authors Judit Hagymásy, Ákos Józwiak and Dalma Hosszú.

The collaborative group **EuroACT Working Group** was erroneously not credited with authorship in the published article. The consortium should be credited with authorship.

The list of members of the EuroACT Working Group was omitted from the published article. The section Group Members of the EuroACT Working Group has been added to the article as follows: Attila Imre, Anna Bögös, Natacha Bolaños, Susanna Leto di Priolo, Kate Morgan.

The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.